Hexavalent chromium Cr(VI) up-regulates COX-2 expression through an NF[kappa]B/c-Jun/AP-1-dependent pathway.
BACKGROUND: Hexavalent chromium [Cr(VI)] is recognized as a human carcinogen via inhalation. However, the molecular mechanisms by which Cr(VI) causes cancers are not well understood.
OBJECTIVES: We evaluated cyclooxygenase-2 (COX-2) expression and the signaling pathway leading to this induction due to Cr(VI) exposure in cultured cells.
METHODS: We used the luciferase reporter assay and Western blotting to determine COX-2 induction by Cr(VI). We used dominant negative mutant, genetic knockout, gene knockdown, and chromatin immunoprecipitation approaches to elucidate the signaling pathway leading to COX-2 induction.
RESULTS: We found that Cr(VI) exposure induced COX-2 expression in both normal human bronchial epithelial cells and mouse embryonic fibroblasts in a concentration-and time-dependent manner. Deletion of IKK[beta] [inhibitor of transcription factor NF[kappa]B (I[kappa]B) kinase [beta]; an upstream kinase responsible for nuclear factor [kappa]B (NF[kappa]B) activation] or overexpression of TAM67 (a dominant-negative mutant of c-Jun) dramatically inhibited the COX-2 induction due to Cr(VI), suggesting that both NF[kappa]B and c-Jun/AP-1 pathways were required for Cr(VI)-induced COX-2 expression. Our results show that p65 and c-Jun are two major components involved in NF[kappa]B and AP-1 activation, respectively. Moreover, our studies suggest crosstalk between NF[kappa]B and c-Jun/AP-1 pathways in cellular response to Cr(VI) exposure for COX-2 induction.
CONCLUSION: We demonstrate for the first time that Cr(VI) is able to induce COX-2 expression via an NF[kappa]B/c-Jun/AP-1-dependent pathway. Our results provide novel insight into the molecular mechanisms linking Cr(VI) exposure to lung inflammation and carcinogenesis.
KEY WORDS: AP-1, chromium, c-Jun, COX-2, NF[kappa]B. Environ Health Perspect 120:547-553 (2012). http://dx.doi.org/10.1289/ehp.1104179 [Online 6 January 2012]
Chromium (Cr) is a ubiquitous metal found in animals, plants, rocks, soil, and air (Hill et al. 2008). Exposure to hexavalent chromium [Cr(VI)] occurs in multiple occupational environments, and the approximate daily absorbed dose of Cr(VI) is 83-1,700 [micro]g/kg/day (Beveridge 2010). The International Agency for Research on Cancer (1980) has classified Cr(VI) as a known human carcinogen. Previous in vivo studies strongly indicated that there is an association between Cr(VI) exposure and airway inflammation and lung carcinogenesis (Beaver et al. 2009a, 2009b; Zeidler-Erdely et al. 2008). However, the molecular mechanisms by which Cr(VI) induces lung inflammation and cancers are not yet well understood.
Prostaglandin (PG) is an important mediator at all stages of cancer development (Menter 2002). Cyclooxygenase (COX) is the rate-limiting enzyme in the synthesis of PGs (Rao et al. 2004). The COX enzyme system is composed of two isoenzymes: COX-1, the constitutive isoform, and COX-2, the inducible protein (Davies et al. 2002). COX-2 can undergo rapid induction in response to many factors, such as growth factors and cytokines (Kirschenbaum et al. 2001), and is highly expressed in a variety of human cancers and cancer cell lines (Liao and Milas 2004).COX-2 overexpression is associated with more aggressive biological tumor behaviors (Liao and Milas 2004), and the inhibition of COX-2 has been regarded as an effective anticancer strategy (Davies et al. 2002). Thus, identification of the potential involvement of COX-2 and molecular mechanisms responsible for COX-2 induction due to Cr(VI) exposure will provide significant insight into understanding Cr(VI) lung inflammatory and carcinogenic effects. In the present study, we investigated the potential effects of Cr(VI) on COX-2 expression and molecular mechanisms leading to this induction in cell culture models.
Materials and Methods
Cell culture and reagents. Mouse embryonic fibroblasts (MEFs) were cultured in 37[degrees]C with 5% [CO.sub.2] in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS),1% penicillin/streptomycin, and 2 mM L-glutamine (all from Life Technologies, Grand Island, NY, USA) (Song et al. 2008). Normal human bronchial epithelial cells (NHBECs) were cultured in a modified LHC-9 medium (BioWhittaker, Inc., Walkersville, MD, USA) supplemented with 52 [micro]g/mL bovine pituitary extract, 0.5 [micro]g/mL hydrocortisone, 0.5 ng/mL human epidermal growth factor, 0.5 [micro]g/mL epinephrine, 10 [micro]g/mL transferrin, 5 [micro]g/mL insulin, 0.1 ng/mL retinoic acid, 6.5 ng/mL triiodothyronine, 50 [micro]g/mL gentamicin, and 50 ng/mL amphotericin-B. We purchased antibodies specific for I[kappa]B[alpha] [inhibitor of transcription factor NF[kappa]B-[alpha]), phosphorylated I[kappa]B[alpha] (P-I[kappa]B[alpha]), c-Jun, phosphorylated c-Jun (P-c-Jun73), and I[kappa]B kinase [beta] (IKK[beta]) from Cell Signaling Technology (Beverly, MA, USA); Antibodies against COX-2, Jun-B, Jun-D, c-Fos, Fra-1, and p65 from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-[beta]-actin antibody from Sigma (St. Louis, MO USA) and Sungene Biotech (Tianjin, China); and anti-p50 antibody from Abcam (Cambridge, MA, USA). The luciferase assay substrate was purchased from Promega (Madison, WI, USA), and sodium chromate (N[a.sub.2]Cr[O.sub.4]) was purchased from Aldrich (Milwaukee, WI, USA).
Plasmid constructs and transfection. We purchased AP-1-luciferase (AP-1-Luc) plasmid from Stratagene (Santa Clara, CA, USA). The COX-2-Luc reporter plasmid, nuclear factor of activated T cells (NFAT)-Luc reporter plasmid, nuclear factor [kappa]B (NF[kappa]B)-Luc reporter plasmid, dominant-negative mutant of IKK[beta] (IKK[beta]-KM), hemagglutinin-tagged IKK[beta] (HA-IKk[beta]), and c-Jun dominant-negative mutant (pcDNA3.1/His-TAM67), as well as [IKK[beta].sup.-/-] and [IKK[alpha].sup.-/-] MEFs and their corresponding wild-type (WT) MEFs, were described previously (Ding et al. 2006b; Ouyang et al. 2007a; Tang et al. 2001). Transfection experiments were performed with Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. The stable transfectants were established and cultured in antibiotic-free DMEM for at least two passages before performing experiments.
Reverse-transcription polymerase chain reaction (RT-PCR). After the cells were treated with N[a.sub.2]Cr[O.sub.4], total RNA was extracted using TRIZOL reagent (Invitrogen) following the manufacturer's instructions. First-strand cDNA was synthesized with [oligo(dT).sub.20] primers using the SuperScript III First-Strand Synthesis System for RT-PCR; Invitrogen), and I [mu]g of total RNA was used to perform reverse transcription. Specific primer pairs were designed for amplifying murine cox-2 (forward, 5'-tca ccc gag gac tcc gcc-3'; reverse, 5'-tcc tgc ccc aca gca aac tgc-3') and [beta]-actin (forward, 5'-gac gat gat att gcc gca ct-3'; reverse, 5'-gat ace acg ctt gct ctg ag-3'). For specific amplifications, 50 ng of cDNA templates was used.
Luciferase reporter assay. MEFs transfected with the luciferase reporter constructs were seeded into 96-well plates (8 x [10.sup.3]/well) and subjected to various treatments when cultures reached 80-90% confluence. For ultraviolet B (UVB) radiation, culture plates were covered with a thin layer of fresh medium (0.1% FBS-DMEM) and exposed to UVB light for 1 min, corresponding to a dose of 1 kJ/[m.sup.2], as reported previously (Song et al. 2007). The UVB light source (UVP Inc., Upland, CA, USA) emitted > 95% 302-nm UVB light. Luciferase activity was determined using a luminometer (Wallac 1420 Victor 2 multilabel counter system; PerkinElmer, Waltham, MA, USA) as described previously (Huang et al. 2002). The results are expressed as relative activity normalized to the luciferase activity in the control cells without treatment.
Western blotting assay. Cells (2 x [10.sup.5]) were seeded and cultured in each well of six-well plates until 70-80% confluence. The cells were exposed to Cr(VI) at varying doses and time points and then extracted with sodium dodecyl sulfate sample buffer as previously described (Ouyang et al. 2007b). The cell extracts were used for Western blotting with specific antibodies. The protein band, specifically bound to the primary antibody, was detected using an anti-rabbit IgG-alkaline phosphatase (AP)-linked antibody and an electrochemi-fluorescence (ECF) Western blotting system (Amersham Biosciences, Piscataway, NJ, USA). The images were obtained by scanning using the Storm 860 phosphoimager (Molecular Dynamics, Sunnyvale, CA, USA)
Electrophoretic mobility shift assay (EMSA) and super gel shift. We performed the EMSA using the LightShift Chemiluminescent EMSA Kit (Pierce, Rockford, IL, USA) according to the manufacturer's instructions. Nuclear extracts were isolated with a Nuclear/Cytosol Fractionation Kit (Rio Vision, Mountain View, CA, USA). The specific probe pair designed for activated NF[kappa]B was 5'-agt tga ggg gac ttt ccc agg c-3' and 5 '-gcc tgg gaa agt ccc ctc aac t-3'. The specific probe pair designed for activated AP-1 was 5'-cgc ttg atg agt cag ccg gaa-3' and 5'-ttc cgg ctg act cat caa gcg-3'. The probes were conjugated with biotin by a Biotin 3' End DNA Labeling Kit (Pierce) following the manufacturer's instructions. Nuclear protein (4 [micro]g) was subjected to the gel shift assay by incubation with 1 [micro]g poly(dI-dC) DNA carrier in DNA binding buffer [10 mM Tris (pH 8.0), 150 mM potassium chloride, 2 mM EDTA, 10 mM magnesium chloride, 10 mM dithiothreitol, 0.1% bovine serum albumin, 20% glycerol]. The biotin-labeled double-stranded oligonucleotide (1 [micro]L) was then added, and the reaction mixture was incubated at room temperature for 50 min. For competition experiments, a 50-fold molar excess of the unlabeled double-stranded oligonucleotide was added before the addition of the labeled probe. For the super gel shift assay, nuclear extracts were incubated with 2 [micro]g antibody for 30 min at 4[degrees]C before addition of the probe. DNA-protein complexes were resolved by electrophoresis on 5% non-denaturing glycerol-polyacrylamide gels. The luminescent signal was developed by a LightShift[R] Chemiluminescent EMSA Kit and detected by an automatic developing machine.
Chromatin immunoprecipitation (ChIP) assay. The ChIP assay was performed using the EZ ChIP kit (Upstate, Billerica, MA, USA) according to the manufacturer's instructions. Briefly, cells were either untreated or treated with Cr (20 [micro]M) for 12 hr, and then genomic DNA and the proteins were cross-linked with 1% formaldehyde. The cross-linked cells were pelleted, resuspended in lysis buffer, and sonicated to generate 200-to 500-bp chromatin DNA fragments. After centrifugation, the supernatants were diluted 10-fold and then incubated with anti-p65 or anti-c-Jun anti-bodies, respectively, or the control rabbit IgG at 4[degrees]C overnight. The immune complex was captured by protein G agarose saturated with salmon sperm DNA and then eluted with elution buffer. DNA-protein cross-linking was reversed by heating at 65[degrees]C for 4 hr. DNA was purified and subjected to PCR analysis.
To specifically amplify the region containing the putative NF[kappa]B-responsive elements on the mouse COX-2 promoter, we performed PCR using the following primers: 5'-ctg acg agc gag cac gtc-3' (forward) and 5'-ttt ggc ctc tgg ggt ttc-3' (reverse). To specifically amplify the region containing the putative AP-1-responsive elements on the mouse COX-2 promoter, PCR was performed with the following primers: 5'-ttc cca taa gac tcc g-3' (forward) and 5'-gct tca tgt gca agc t-3' (reverse). Primers targeting the region 1 kb upstream of the NF[kappa]B and AP-1 binding sites on the COX-2 promoter were also used in the PCR analysis to support the specificity of the ChIP assay: 5'-tga ttt ggt ttg gga ca-3' (forward) and 5'-ctg gag gac aag agc agt-3' (reverse).
Clonogenic survival assay. MEFs were treated with Cr(VI) at 5 [micro]M and 20 [micro]M for 6 and 12 hr and recovered for 24 hr in normal culture medium. Cells were then plated at 500 cells/dish in 100-mm cell culture dishes and cultured for 2 weeks. Cells were stained with Giemsa solution, and the number of colonies was counted and presented as mean [+ or -] SD (n = 3).
Statistical analysis. We used the Student's t-test to determine the significance of difference in COX-2 induction and AP-1, NFAT, or NF[kappa]B activation in luciferase reporter assays among various groups. The statistical significance level was set at p < 0.05.
Cr(VI) exposure induced COX-2 expression. As shown in Figure 1A, treatment of MEFs with Cr(VI) resulted in an increase in COX-2 protein expression in a dose-and time-dependent manner. We observed marked induction at 12 hr and 24 hr after exposure. Cr(VI) exposure was previously reported to induce either cell growth arrest and/or apoptosis in a dose-, time-and, cell-type-dependent manner (Wang et al. 2004). To evaluate the cytotoxicity of Cr(VI) in our experimental system, we subjected Cr(VI)-treated MEFs to a colony-survival assay. Results showed only marginal toxicity on MEFs exposed to 20 [micro]M Cr(VI) after 12 hr of exposure, whereas there was no observable cytotoxicity at 5 [micro]M (Figure 1E). These results are consisted with a previous report showing that the viability of HaCaT (human keratinocyte) cells is not affected at Cr(VI) concentrations as high as 30 [micro]M (Wang et al. 2010). Consistent with protein induction, marked induction of COX-2 mRNA by 20 [micro]M Cr(VI) was present as early as 6 hr after exposure, suggesting that Cr(VI) might induce COX-2 expression at a transcriptional level (Figure 1B). To test this notion, we investigated the effects of Cr(VI) on COX-2 promoter activity in the stable transfectant of COX-2 promoter-driven luciferase reporter. As shown in Figure 1F and 1G, treatment with Cr(VI) resulted in a marked increase in COX-2 promoter activity. This induction was also observed with 20 [micro]M Cr(VI) as early as at 6 hr after exposure (Figure 1F), which is consistent with the results of the RT-PCR assay. The respiratory tract is the primary target organ of Cr(VI) (Goldoni et al. 2008). Thus, we used NHBECs to test the effect of Cr(VI) on COX-2 expression. Cr(VI) exposure did cause COX-2 expression in NHBECs (Figure 1C, D). Collectively, these results indicate that Cr(VI) is able to induce COX-2 expression in both MEFs and NHBECs.
Cr(VI) exposure induced the activation of NF[kappa]B and AP-1 but not NFAT. Cr(VI) treatment did not result in observable NFAT activation (Figure 2A), whereas UVB exposure, the positive control, resulted in significant NFAT activation (Figure 2B) in the same stable NFAT-Luc reporter transfectant. In contrast to NEAT, NF[kappa]B activation was significantly increased by Cr(VI) treatment in the NF[kappa]B-Luc reporter assay (Figure 2C). The activation of the NF[kappa]B pathway by Cr(VI) was further verified by the observation of increased 1[kappa]B[alpha] phosphorylation and degradation in the Western blotting assay (Figure 2E) and NF[kappa]B DNA binding activity analyzed by an EMSA assay (Figure 2F). We further determined the involvement of the AP-1 pathway in cells exposed to Cr(VI). As shown in Figure 2D and 2G, treatment of cells with Cr(VI) for 6 hr also led to marked AP-1 induction in the AP-1-Luc reporter assay (Figure 2D) and the AP-1 EMSA assay (Figure 2G). These results demonstrate that Cr(VI) exposure induced activation of NF[kappa]B and AP-1 but not NFAT.
DNA binding activity of NF[kappa]B induced by Cr(VI) reached to peak at 3 hr (Figure 2F), whereas the maximum AP-I DNA binding activity was achieved at 9 hr after exposure (Figure 2G). The difference could be due to the differential pathways responsible for activation of NF[kappa]B and AP-1. NF[kappa]B activation is fully dependent on IKK[beta]/I[kappa]B phosphorylation/degradation (Song et al. 2006), whereas AP-1 activation is dependent on both c-Jun phosphorylation and increased c-Jun protein expression (Huang et al. 1999a, 1999b). The induction of c-Jun protein expression may lead to the delay of maximum AP-1 activation compared with the peak of NF[kappa]B activation. Cr(VI) has been reported to inhibit tumor necrosis factor-[alpha]-induced NF[kappa]B transcriptional competence through inhibiting interactions with coactivators of transcription rather than DNA binding (Shumilla et al. 1999). Another study found that Cr(VI) prevented the benzo[aJpyrene-dependent release of histone deacetylase-1 from cytochrome P450 lal chromatin and blocked p300 recruitment (Wei et al. 2004).
IKK[beta] is required for CI(VI)-induced COX-2 expression. To clarify the potential role of IKK[beta] in Cr(VI)-induced COX-2 expression, we used IKK[beta]-KM, an inactive mutant of IKK[beta], and [IKK[beta].sup.-/-]MEFs. As shown in Figure 3A, overexpression of IKK[beta]-KM in MEFs inhibited Cr(VI)-induced COX-2 expression in the COX-2-Luc reporter assay. The knockout of IKK[beta] (Figure 3B) impaired the phosphorylation and degradation of its downstream target I[kappa]B[alpha] after Cr(VI) treatment (Figure 3C), indicating the necessary role of IKK[beta] in Cr(VI)-induced NF[kappa]B activation. Cr(VI)-induced COX-2 protein expression was consistently blocked in [IKK[beta].sup.-/-] cells (Figure 3D). Moreover, reconstituted expression of IKK[beta] in [IKK[beta].sup.-/-] cells restored COX-2 induction (Figure 3E). Our results demonstrate that IKK[kappa] was required for COX-2 induction after Cr(VI) exposure. Overexpression of IKK[beta]-KM was not able to completely inhibit COX-2 promoter-driven luciferase transcription (Figure 3A), whereas IKK[beta] deletion ([IKK[beta].sup.-/-]) was able to block COX-2 expression completely (Figure 3D). These results suggest that IKK[beta]-KM overexpression was not able to completely impair endogenous 1KK[beta] function.
The potential role of NF[kappa]B p65 in the regulation of COX-2 expression due to Cr(VI) exposure. NF[kappa]B components are expressed in a variety of cell types (Karin and Gruen 2005). In a previous study we showed that the NF[kappa]B p65 subunit, but not the p50 subunit, is required for nickel-induced COX-2 expression in Beas-2B cells (Ding et al. 2006b). In the present study, we determined the differential involvement of p65 and p50 subunits in Cr(VI)-induced COX-2 expression. We performed a super gel shift assay in the presence of the antibodies specific for p65 or p50. As shown in Figure 3F, selective reduction of the p65 band was observed using anti-p65 antibody, whereas no reduction of DNA binding activity was observed with anti-p50 antibody. Incubation of cell nucleus extracts with anti-p65 antibody reduced the extract protein binding to the NF[kappa]B probe but did not cause the supershift hand. The explanation for this may be that binding of anti-p65 antibody to p65 protein changes the p65 protein conformation and in turn leads to p65 losing its binding activity to the NF[kappa]B probe. These results suggest that p65 might be the major component involved in NF[kappa]B activation after Cr(VI) exposure. This notion is further supported by ChIP assay data. As shown in Figure 3G, Cr(VI) treatment markedly enhanced recruitment of the p65 subunit to its binding site in COX-2 promoters, whereas control IgG and primers targeting the DNA sequence located at approximately 1 kb upstream of the NF[kappa]B binding site in the COX-2 promoter did not show detectable PCR products (Figure 3G). Taken together, these results demonstrate that NF[kappa]B p65, rather than the p50 subunit, plays a key role in NE[kappa]B activation and COX-2 induction after Cr(V1) exposure.
Involvement of c-Jun/AP-1 in Cr(VI)-induced COX-2 expression. Different AP-1 dimers play different roles in the regulation of cellular function and carcinogenesis (Song et al. 2008). Western blotting shows that Cr(VI) exposure resulted in c-Jun phosphorylation, but we observed no activation of other AP-1 members Jun B, Jun D, c-Fos, or Fra-1 (Figure 4A). To determine the role of c-Jun in Cr(VI)-induced AP-1 activation, we performed a super gel shift assay using antibodies specific for c-Jun and c-Fos. As shown in Figure 4B, we observed a selective supershift band of c-Jun in cell extracts from Cr(VI)-treated cells, but no c-Fos supershift band was observable, suggesting that c-Jun was the major component involved in AP-1 activation due to Cr(VI) exposure. COX-2 has been shown to be a typical AP-1-regulated gene in several experimental systems (Zhang et al. 2010). Thus, we determined the recruitment of c-Jun to the COX-2 promoter region using the ChIP assay. The detection of the COX-2 promoter in the antibody-captured genomic DNA fragments was performed by PCR amplification with primers designed to specifically recognize the region containing AP-1-responsive elements. Anti-c-Jun antibody strongly coimmunoprecipitated the target COX-2 promoter region DNA in Cr(VI)-treated cell extract but not in the control cell extract (Figure 4C), indicating the inducible recruitment of c-Jun to the endogenous COX-2 promoter after Cr(VI) exposure. This demonstrates Cr(VI)-inducible recruitment of AP-1 onto the endogenous COX-2 promoter region (Figure 4C), suggesting that AP-1 might play a role in the regulation of COX-2 expression due to Cr(VI) exposure. To test this notion, we used TAM67, a dominant negative mutant of c-Jun. The ectopic expression of TAM67 in WT cells attenuated Cr(VI)-induced c-Jun phosphorylation in MEFs (Figure 4E). Unlike overexpression of IKK[beta]-KM in MEFs (Figure 3A), COX-2 promoter-driven luciferase transcription was impaired in WT/TAM67 transfectant (Figure 4D), suggesting that TAM67 overexpression was able to block the endogenous c-Jun function. COX-2 protein induction by Cr(VI) was also blocked (Figure 4E). These results demonstrate that c-Jun activation is essential for COX-2 induction after Cr(VI) exposure.
Crosstalk between AP-1 and NFK[beta] pathways after Cr(VI) exposure. Crosstalk between AP-1 and NF[kappa]B has been reported to be responsible for the synergistic increase in their activity in the regulation of target gene expression (Adcock 1997). Thus, we determined the potential relationship of these two transcription factors in response to Cr(VI) exposure in cells. We used [IKK[beta].sup.-/-]MEFs to examine whether the impairment of the NF[kappa]B pathway could affect c-Jun phosphorylation. Impairment of the NF[kappa]B pathway inhibited c-Jun phosphorylation (Figure 5A), suggesting that NF[kappa]B activation has a positive effect on c-Jun activation after Cr(VI) exposure. To further reveal the potential effects of c-Jun/AP-1 on NF[kappa]B activation, we used a dominant negative mutant of c-Jun (T-AM67). As shown in Figure 5B, ectopic expression of TAM67 had an inhibitory effect on I[kappa]B[alpha] phosphorylation, suggesting that the phosphorylation of c-Jun was also involved in the regulation of the NF[kappa]B pathway. Taken together, the AP-1 and NF[kappa]B pathways did show crosstalk after Cr(VI) treatment, which might play a role in Cr(VI)-induced COX-2 induction and carcinogenesis (Figure 5C).
The data we present here indicate that Cr(VI) induced expression. of COX-2 and activation of AP-1 and NF[kappa]B, and show that both AP-1 and NF[kappa]B are required for Cr(VI)-induced COX-2 expression. Our data also indicate the presence of crosstalk between the NF[kappa]B and AP-1 pathways after Cr(VI) exposure, which mainly occurred via IKK[beta]/p65-dependent and c-Jun dependent pathways. Considering the important role Of COX-2 in the mediation of chronic inflammation and lung carcinogenesis, we anticipated that activation of NF-KB and AP-1 pathways and their crosstalk in the regulation of COX-2 expression might be key factors in Cr(VI)-induced lung carcinogenesis. Further elucidating the relationship among chronic inflammation, COX-2 induction, and lung carcinogenic effect after various doses of Cr(VI) exposure in vivo animal models will be a major focus for future investigations in our laboratory, which might help determine a threshold dose for lung carcinogenesis of Cr(VI) exposure.
Inflammation is implicated in Cr(VI)induced human lung cancer development. Repetitive exposure to Cr(VI) results in persistent inflammation, and such an inflammatory microenvironment can further promote lung carcinogenesis (Beaver et al. 2009a, 2009b). COX-2 plays an important role in the development of various types of cancer, including lung cancer (Sahin et al. 2009), and drugs targeting this enzyme have achieved widespread clinical use (Bertagnolli 2007). Our previous studies have shown that COX.-2 induction is involved in several carcinogenic responses (Ding et al. 2006a, 2006h; Li et al. 2006). In the present study, we initially found that exposure to Cr(VI) induced COX-2 expression in both NHBECs and MEFs. Considering the critical role of COX-2 in the inflammatory processes of cancer and the importance of an inflammatory microenvironment during carcinogenesis after Cr(V1) exposure, our results may shed light into the mechanisms of Cr(VI)-induced carcinogenic effects.
The COX-2 promoter region contains the binding sites of three major transcription factors: NF[kappa]B (Crofford et al. 1997), AP-1 (Subbaramaiah et al. 2002), and NFAT (Iniguez et al. 2000). These three factors have been reported to be major mediators for the regulation of cell proliferation, differentiation, and transformation (Huang et al. 1999a, 1999b). In the present study, we observed that Cr(VI) exposure resulted in the activation of NF[kappa]B and AP-1, whereas there was no observable NFAT activation, which is consistent with published studies showing that Cr(VI) exposure leads to the activation of NF[kappa]B and AP-1 in an oxidative-stress-dependent manner (Yao et al. 2008). NF[kappa]B activation has been reported to be involved in the development of several cancers (Biswas et al. 2004; Wang et al. 2003). Our published studies have shown that NF[kappa]B activation is involved in cellular responses to several environmental carcinogens (Ding et al. 2007; Ouyang et al. 2007b). In the present study, we found that IKK[betta] was critical for Cr(VI)-induced NF[kappa]B activation and COX-2 expression. In addition, we showed that p65, rather than p50, was required for Cr(VI)-induced NF[kappa]B activation and COX-2 expression. We observed that Cr(VI) exposure induces NF[kappa]B activation via an IKK[beta]/p65-dependent pathway, which further leads to COX-2 induction. Cr(VI) increases formation of reactive oxygen species (ROS) in certain cell types (Wang et al. 2010), and the inductive COX-2 expression of manganese is accompanied by generation of oxidative stress and increased NF[kappa]B and AP-1 DNA binding activities (Chen et al. 2007). Thus, we anticipate that ROS generation may also be involved in the activation of NF[kappa]B and AP-1, which further leads to COX-2 expression.
The c-Jun/AP-1 pathway is crucial for COX-2 induction caused by some environmental stresses (Ouyang et al. 2007a; Zhang et al. 2008). Because of the multiple functions of AP-1 proteins, the selection of the different AP-1 dieters is considered as another mechanism for the modulation of AP-1 activity (Song et al. 2008). The results of the present study indicate that AP-1 activation due to Cr(VI) exposure mainly involves c-Jun phosphorylation. The predominant role of c-Jun in Cr(VI)-induced AP-1 transactivation and COX-2 induction was further confirmed by super gel shift assay and ChIP assay. Furthermore, transfection with the dominant negative c-Jun mutant (TAM67) blocked Cr(VI)-induced COX-2 expression. In addition, the knockout of IKK[beta] impaired Cr(VI)-induced c-Jun phosphorylation, whereas inhibition of the c-Jun/AP-1 pathway by overexpression of TAM67 also inhibited Cr(VI)-induced I[kappa]B[alpha] phosphorylation, suggesting crosstalk between the c-Jun/AP-1 pathway and the IKK[beta]/NF[kappa]B pathway in the Cr(VI) response. Because both the c-Jun/AP-I pathway and the IKKI3/NFKB pathway are crucial for COX-2 induction, we anticipate that this crosstalk may play a key role in Cr(VI)-induced COX-2 expression, which provides a novel model of the interaction between NFKB and AP-I pathways for environmental responses. Considering that inhibition of NFKB, AP-I, and COX-2 has been proposed as potential anticancer strategies, our results may lead to new targets for chemoprevention of Cr(VI)-induced human carcinogenesis.
Adcock IM. 1997. Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Monaldi Arch Chest Dis 52(2):178-186.
Beaver LM, Stemmy EJ, Constant SL, Schwartz A, Little LG, Gigley JP, et al. 2009a. Lung injury, inflammation and Akt signaling following inhalation of particulate hexavalent chromium. Toxicol Appl Pharmacol 235(11:47-56.
Beaver LM, Stemmy EJ, Schwartz AM, Damsker JM, Constant SL, Ceryak SM, et al. 2009b. Lung inflammation, injury, and proliferative response after repetitive particulate hexavalent chromium exposure. Environ Health Perspect 117:1896-1902.
Bertagnolli MM. 2007. Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol 8(5):439-443.
Beveridge R, Pintos J, Parent ME, Asselin J, Siemiatycki J. 2010. Lung cancer risk associated with occupational exposure to nickel, chromium VI, and cadmium in two population-based case-control studies in Montreal. Am J Ind Med 53(5):476-485.
Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, et al. 2004. NE-[kappa]B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101(27):1 0137-10142.
Chen CJ, Liao SL, Ou YC, Chen SY, Chiang AN. 2007. Induction of cyclooxygenase-2 expression by manganese in cultured astrocytes. Neurochem Int 50(7-81:905-915.
Crofford LJ, Tan B, McCarthy CJ, H1a T. 1997. Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum 40(4226-236.
Davies G, Martin LA, Sacks N, Dowsett M. 2002. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 13(5):669-678.
Ding J, Li J, Xue C, Wu K, Ouyang W, Zhang D, et al. 2006a. Cyclooxygenase-2 induction by arsenite is through a nuclear factor of activated T-cell-dependent pathway and plays an antiapoptotic role in Beas-2B cells. J Biol Chem 281(34):24405-24413.
Ding J, Wu K, Zhang D, Luo W, Li J, Ouyang W, et al. 2007. Activation of both nuclear factor of activated T cells and inhibitor of nuclear factor-[kappa]B kinase [beta]-subunit-/nuclear factor-[kappa]B is critical for cyclooxygenase-2 induction by benzo[a]pyrene in human bronchial epithelial cells. Cancer Sci 98(91:1323-1329.
Ding J, Zhang X, Li J, Song L, Ouyang W, Zhang D, et al. 2006b. Nickel compounds render anti-apoptotic effect to human bronchial epithelial Beas-2B cells by induction of cyclooxygenase-2 through an IKK[beta]/p65-dependent and IKK[alpha]-and p50-independent pathway. J Biol Chem 281(51):39022-39032.
Goldoni M, Cagliari A, Corradi M, Poli D, Rusca M, Carbognani P, et al. 2008. Chromium in exhaled breath condensate and pulmonary tissue of non-small cell lung cancer patients. Int Arch Occup Environ Health 81(4):487-493.
Hill R, Leidal AM, Madureira PA, Gillis LD, Cochrane HK, Waisman DM, et al. 2008. Hypersensitivity to chromium-induced DNA damage correlates with constitutive deregulation of upstream p53 kinases in p21-/-HCT116 colon cancer cells. DNA Repair (Amst) 7(2):239-252.
Huang C, Huang Y, Li J, Hu W, Aziz R, Tang MS, et al. 2002. Inhibition of benzo(a)pyrene diol-epoxide-induced trans-activation of activated protein 1 and nuclear factor [kappa]B by black raspberry extracts. Cancer Res 62(23):6857-6863.
Huang C, Ma WY, Dong Z. 1999a. The extracellular-signal-regulated protein kinases (Erks) are required for UV-induced AP-1 activation in JB6 cells. Oncogene 18(18):2828-2835.
Huang C, Ma WY, Li J, Goranson A, Dong Z. 1999b, Requirement of Erk, but not JNK, for arsenite-induced cell transformation. J Biol Chem 274(21):14595-14601.
Iniguez MA, Martinez-Martinez S, Punzon C, Redondo JM, Fresno M. 2000. An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 275(31):23627-23635.
International Agency for Research on Cancer. 1980. Some Metals and Metallic Compounds. IARC Monogr Eval Carcinog Risk Chem Hum 23:1-415.
Karin M, Greten FR. 2005. NE-[kappa]B: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10):749-759.
Kirschenbaum A, Liu X, Yea S, Levine AC. 2001. The role of cyclooxygenase-2 in prostate cancer. Urology 58(2 suppl 1):127-131.
Li J, Song L, Zhang D, Wei L, Huang C. 2006. Knockdown of NFAT3 blocked TPA-induced COX-2 and iNOS expression, and enhanced cell transformation in C141 cells. J Eell Biochem 99(4):1010-1020.
Liao Z, Miles L. 2004. COX-2 and its inhibition as a molecular target in the prevention and treatment of lung cancer. Expert Rev Anticancer Ther 4(4):543-560.
Menter DG. 2002. Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention. Expert Opin Investig Orugs 11(12)1749-1764.
Ouyang W, Ma Q, Li J, Zhang D, Ding J, Huang Y, et al. 2007a. Benzo[a]pyrene diol-epoxide (B[a]PDE) upregulates COX-2 expression through MAPKs/AP-1 and IKK[beta]/NE-[kappa]B in mouse epidermal CI41 cells. Mal Carcinog 46(1):32-41.
Ouyang W, Zhang D, Ma Q, Li J, Huang C. 2007b. Cyclooxygenase-2 induction by arsenite through the IKK[beta]/NF[kappa]B pathway exerts an antiapoptotic effect in mouse epidermal C141 cells. Environ Health Perspect 115:513-518.
Rao M, Yang W, Seifalian AM, Winslet MC. 2004. Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer. Int J Colorectal Dis 19(1):1-11.
Sahin M, Sahin E, Gumuslu S. 2009. Cyclooxygenase-2 in cancer and angiogenesis. Angiology 60(2):242-253.
Shumilla JA, Broderick RJ, Wang Y, Barchowsky A. 1999. Chromium(VI) inhibits the transcriptional activity of nuclear factor-[kappa]B by decreasing the interaction of p65 with cAMP-responsive element-binding protein-binding protein. J Biol Chem 274(51):36207-36212.
Song L, Li J, Hu M, Huang C. 2008. Both IKK[alpha] and IKK[beta] are implicated in the arsenite-induced AP-1 transactivation correlating with cell apoptosis through NF-[kappa]B activity-independent manner. Exp Cell Res 314(11-12)1187-2198.
Song L, Li J, Ye J, Yu G, Ding J, Zhang D, et al. 2007. p85 acts as a novel signal transducer for mediation of cellular apoptotic response to UV radiation. Mol Cell Bid 27(7)1713-2731.
Song L, Li J, Zhang D, Liu Z-G, Ye J, Zhan Q, et al. 2006. IKK[beta] programs to turn on the GADD45a-MKK4-JNK apoptotic cascade specifically via p50 NE-[kappa]B in arsenite response. J Cell Biol 175(4):607-617.
Subbaramaiah K, Cole PA, Dannenberg AJ. 2002. Retinoids and carnosol suppress cyclooxygenase-2 transcription by CREB-binding protein/p300-dependent and-independent mechanisms. Cancer Res 62(9):2522-2530.
Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M, et al. 2001. Inhibition of JNK activation through NF-[kappa]B target genes. Nature 414(6861)113-317.
Wang Q, Wang X, Evers BM. 2003. Induction of clAP-2 in human colon cancer cells through PKC[delta]/NF-[kappa]B. J Biol Chem 278(51):51091-51099.
Wang S, Chen F, Zhang Z, Jiang B, Jia L, Shi XL 2004. NF-[kappa]B prevents cells from undergoing Cr(VI)-induced apoptosis. Mol Cell Biochem 255(1-2):129-137.
Wang YJ, Wang BJ, Sheu HM, Guo YL, Lee YH, Lai CS, et al. 2010. Hexavalent chromium induced ROS formation, Akt, NF-[kappa]B, and MAPK activation, and TNF-[alpha] and IL-l[alpha] production in keratinocytes. Toxicol Lett 198(2):216-224.
Wei YD, Tepperman K, Huang MY, Sartor MA, Puga A. 2004. Chromium inhibits transcription from polycyclic aromatic hydrocarbon-inducible promoters by blocking the release of histone deacetylase and preventing the binding of p300 to chromatin. J Biol Chem 279:4110-4119.
Yao H, Guo L, Jiang BH, Luo J, Shi X. 2008. Oxidative stress and chromium(VI) carcinogenesis. J Environ Pathol Toxicol Oncol 27(2):77-88.
Zeidler-Erdely P, Kashon M, Battelli L, Young S-H, Erdely A, Roberts J, et al. 2008. Pulmonary inflammation and tumor induction in lung tumor susceptible A/J and resistant C57BL/6J mice exposed to welding fume. Part Fibre Toxicol 5(1):12; doi:10.1186/1743-8977-5-12 [Online 8 September 2008].
Zhang D, Li J, Song 1_, Ouyang W, Gao J, Huang C. 2008. A JNK1/AP-/-dependent, COX-2 induction is implicated in 12-0-tetradecanoylphorbol-13-acetate-induced cell transformation through regulating cell cycle progression. Mol Cancer Res 6(1):165-174.
Zhang R, Chen HZ, Liu JJ, Jia YY, Zhang ZQ, Yang RF, et al. 2010. SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages.J Biol Chem 285(10):7097-7110.
Zhenghong Zuo, (1), (2) Tongjian Cai, (1) Jingxia Li, (1) Dongyun Zhang, (1) Yonghui Yu, (1) and Chuanshu Huang (1)
(1.) Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York, USA; (2.) Key Laboratory of the Ministry of Education for Coast and Wetland Ecosystems, School of Life Sciences, Xiamen University, Xiamen, China Address correspondence to C. Huang, Nelson Institute of Environmental Medicine, New York University School of Medicine, 57 Old Forge Rd., Tuxedo, NY 10987 USA. Telephone: (845) 731-3519. Fax: (845) 351-2320. E-mail: firstname.lastname@example.org
This work was supported in part by National Institutes of Health (NIH)/National Cancer Institute grants CA112557-06 and CA119028-05S110 and by NIH/National Institute of Environmental Health Sciences grants ES012451 and ES010344.
The authors declare they have no actual or potential competing financial interests.
Received 7 July 2011; accepted 6 January 2012.